Emotional intelligence scores in children and adolescents with subclinical hypothyroidism—correlation with serum serotonin and thyroid-stimulating hormone (TSH) concentrations

HORMONES ◽  
2021 ◽  
Author(s):  
George Κ. Arianas ◽  
Eirini Kostopoulou ◽  
Anastasios Ioannidis ◽  
Ioannis Dimopoulos ◽  
Christos Chiotis ◽  
...  
Keyword(s):  
Emotional Intelligence ◽  
Children And Adolescents ◽  
Subclinical Hypothyroidism ◽  
Thyroid Stimulating Hormone ◽  
Intelligence Scores ◽  
Serum Serotonin ◽  
Stimulating Hormone

scholarly journals Approach to Subclinical Thyroid Diseas

1970 ◽  
Vol 26 (2) ◽  
pp. 91-96
Author(s):  
Satya Ranjan Sutradhar
Keyword(s):  
Subclinical Hypothyroidism ◽  
Thyroid Dysfunction ◽  
Hormone Level ◽  
Elevated Serum ◽  
Thyroid Stimulating Hormone ◽  
Good Evidence ◽  
Reference Ranges ◽  
Mineral Density ◽  
Asymptomatic Patients ◽  
Stimulating Hormone

Subclinical thyroid dysfunction is defined as an abnormal serum thyroid-stimulating hormone level and free thyroxine and triiodothyronine levels within their reference ranges. The prevalence of subclinical hyperthyroidism is about 2 percent. Subclinical hypothyroidism is found in approximately 4 to 8.5 percent of the population. Most national organizations recommend against routine screening of asymptomatic patients, but screening is recommended for high risk populations. The management of subclinical thyroid dysfunction is controversial. There is good evidence that subclinical hypothyroidism is associated with progression to overt disease. Patients with a serum thyroid-stimulating hormone level greater than 10 mIU/L have a higher incidence of elevated serum low density lipoprotein cholesterol concentrations; however, evidence is lacking for other associations. There is insufficient evidence that treatment of subclinical hypothyroidism is beneficial. A serum thyroid stimulating hormone level of less than 0.1 mIU/L is associated with progression to overt hyperthyroidism, atrial fibrillation, reduced bone mineral density, and cardiac dysfunction. There is little evidence that early treatment alters the clinical course. DOI: 10.3329/jbcps.v26i2.4187 J Bangladesh Coll Phys Surg 2008; 26: 91-96

scholarly journals SAT-447 Thyroid Function, Cardiovascular Disease, and Mortality: A Mediation Analysis

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Kosuke Inoue ◽  
Beate Ritz ◽  
Gregory A Brent ◽  
Ramin Ebrahimi ◽  
Connie Rhee ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Mediation Analysis ◽  
Subclinical Hypothyroidism ◽  
The United States ◽  
Thyroid Stimulating Hormone ◽  
Mediation Effect ◽  
Mortality Data ◽  
All Cause Mortality ◽  
The U.S ◽  
Stimulating Hormone

Abstract Background: Subclinical hypothyroidism is a common clinical entity among the United States (U.S) adults and has been associated with increased risk of cardiovascular disease (CVD) and mortality in some studies. However, the mediation effect of CVD from elevated serum thyroid stimulating hormone (TSH) to mortality has not yet been well established or sufficiently quantified. In this study, we aimed to elucidate the extent to which subclinical hypothyroidism or high-normal thyroid stimulating hormone [TSH] concentrations (i.e. upper normative-range TSH concentrations) contribute to mortality through its effect on CVD among U.S. adults. Methods: This study relies on the U.S. representative samples of 9,020 adults enrolled in the National Health and Nutrition Examination Surveys (NHANES) 2001-2002, 2007-2012 and their mortality data through 2015. We employed Cox proportional hazards regression models to investigate associations between the TSH concentration categories (subclinical hypothyroidism or tertiles of serum TSH concentrations within the reference range) and all-cause mortality. Utilizing mediation analysis within the counterfactual framework, we estimated the mediation effect of CVD on the association between TSH and all-cause mortality. Results: The median duration of follow-up for mortality ascertainment was 7.3 (interquartile range, 5.4–8.3) years, during which 435 deaths from all causes were identified. Subjects with TSH in the subclinical hypothyroidism and the high-normal TSH tertile concentrations were associated with increased all-cause mortality (subclinical hypothyroidism: hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.14–3.19; high-normal TSH: HR, 1.36; 95% CI, 1.07–1.73) compared with the middle-normal TSH tertile concentration. CVD mediated 14.3% and 5.9% of the effects of subclinical hypothyroidism and high-normal TSH on all-cause mortality, respectively, with the CVD mediation effect being most pronounced in women and subjects ≥60 years old. No mediation through CVD was found for low-normal TSH levels and all-cause mortality. Conclusion: CVD mediated the effects of subclinical hypothyroid and high-normal TSH concentrations on all-cause mortality in the U.S. general population. These findings may have potential implications for treatment, and early and more aggressive CVD screening for such at risk populations. Further studies are needed to examine the clinical impact of targeted therapy towards mid-normal TSH concentration.

scholarly journals Hipotiroidismo Subclínico no Idoso

2018 ◽  
Vol 31 (12) ◽  
pp. 766
Author(s):  
Sofia Macedo Silva ◽  
Alexandra Carvalho ◽  
Maria Lopes- Pereira ◽  
Vera Fernandes
Keyword(s):  
Subclinical Hypothyroidism ◽  
The Elderly ◽  
Thyroid Stimulating Hormone ◽  
Reference Level ◽  
Thyroid Antibodies ◽  
Electronic Database Search ◽  
Definition Of ◽  
A Minor ◽  
In The Beginning ◽  
Stimulating Hormone

Introduction: Subclinical hypothyroidism, defined as an increase of thyroid stimulating hormone levels with normal levels of thyroid hormones, could have a multiorgan impact. There seem to be differences in the elderly (over 65 years of age) which indicate that there should be a different approach in terms of diagnosis and the treatment.Material and Methods: Electronic database search and narrative bibliographical review.Results: Different case studies showing the multiorgan consequences of subclinical hypothyroidism suggest that, in the elderly, there is a minor impact or even a lack of repercussion, especially in those over 80 - 85 years old. Additionally, there is evidence indicating that the levels of thyroid stimulating hormone rise with the age of the patient. The standard treatment, in the beginning, is a low dose of levothyroxine when the levels of thyroid stimulating hormone are over 10.0 mIU/L, when there are noticeable symptoms or positive anti-thyroid antibodies. However, the treatment is not consensual when the levels of thyroid stimulating hormone are between 4.5 and 10.0 mIU/L, in such a way that the TRUST study concluded that no benefits have outcome from treating these patients. Discussion: The non-definition of the reference range and the age gap are the key factors that contribute the most to biased results. However, there is consensus regarding non-treatment of mild thyroid dysfunctions (4.5 - 7.0 mIU/L) in the elderly, particularly above 80 years of age. Nevertheless, for positive anti-thyroid antibodies, suggestive ultrasound changes or iatrogenic side effects, the reference level should be 4.5 mIU/L. Conclusion: The general impact of subclinical hypothyroidism is different in elderly people, meaning that an individualized therapeutic approach and long-term monitoring is the appropriate strategy.

scholarly journals A genome-wide association study of thyroid stimulating hormone and free thyroxine in Danish children and adolescents

PLoS ONE ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. e0174204 ◽  
Author(s):  
Tenna Ruest Haarmark Nielsen ◽  
Emil Vincent Rosenbaum Appel ◽  
Mathilde Svendstrup ◽  
Johanne Dam Ohrt ◽  
Maria Dahl ◽  
...  
Keyword(s):  
Association Study ◽  
Children And Adolescents ◽  
Genome Wide Association Study ◽  
Thyroid Stimulating Hormone ◽  
Free Thyroxine ◽  
Genome Wide Association ◽  
Genome Wide ◽  
A Genome ◽  
Stimulating Hormone

scholarly journals Management of Subclinical Hypothyroidism

2014 ◽  
Vol 13 (3) ◽  
pp. 93-96
Author(s):  
Shaheda Ahmed ◽  
A S M Towhidul Alam
Keyword(s):  
Clinical Features ◽  
Subclinical Hypothyroidism ◽  
Thyroid Stimulating Hormone ◽  
Overt Hypothyroidism ◽  
Serum Thyroxine ◽  
Specific Symptoms ◽  
Review Current ◽  
Serum Tsh ◽  
Low Serum ◽  
Stimulating Hormone

Objective: To review current concepts in the management of subclinical hypothyroidism (SCH) in patients with non-specific symptoms.Data sources: A review of articles reported on overt hypothyroidism and subclinical hypothyroidism. Summary of review: In a patient with primary overt hypothyroidism, management is usually straightforward: treatment with thyroxine should be offered to anyone with characteristic clinical features, a raised serum thyroid stimulating hormone (TSH) concentration and a low serum thyroxine (T4) concentration. More difficult is the management of a patient with subclinical hypothyroidism (SCH), in whom serum TSH is slightly raised (5-20 mIU/L) but T3, T4 levels are normal, and who is either asymptomatic or has only non-specific symptoms. Left untreated, some of these patients will eventually develop overt hypothyroidism. This review will address the use of thyroxine in patients with subclinical hypothyroidism.DOI: http://dx.doi.org/10.3329/cmoshmcj.v13i3.21045 

Sign in / Sign up

Export Citation Format

Share Document